risk-adapted treatment of et & pv
Published 2 years ago • 153 plays • Length 2:14Download video MP4
Download video MP3
Similar videos
-
2:13
splicing mutations in post-et/post-pv myelofibrosis
-
1:29
risk-adapted therapy of aml
-
1:50
considerations for risk-adapted therapy in lower-risk mds
-
2:48
epigenetic profiling and machine learning for risk stratification in pediatric all
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:34
perspectives on the management of low and high-risk mds
-
1:31
risk-adjusted safety analysis of pacritinib for patients with mf
-
10:39
risk management in the medical device industry in the eu
-
2:43:21
management antimicrobial series 2: prevention emerging of antibiotic resistance in critical ill
-
1:00:46
ask an mpn expert: tracking and living with mpns
-
1:52
cytoreductive therapy for patients with pv
-
1:51
checkpoint inhibition in the treatment of mpns
-
2:16
phase i study of donor-derived γδ t cells as relapse prophylaxis post haplo/cy
-
3:59
pv: outcomes, unmet needs, and therapeutic strategies
-
2:08
an insight into the current understanding of risk factors for cll
-
2:56
novel drugs for myeloma thromboprophylaxis
-
3:49
the impact of allosct versus blood transfusion & iron chelation on the qol of patients with tdt
-
1:23
management of high-risk newly diagnosed mm
-
4:48
an insight into the management of cytopenias in mf
-
7:03
jak2 v617f vaf as a diagnostic and prognostic marker for polycythemia vera and thrombosis risk
-
1:22
real-world outcomes of patients with mf treated with fedratinib post-ruxolitinib discontinuation